AzTrials
AzTrials

Endometrial CancerNCT02466061

TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors

A study testing Telemedicine Weight Management plus Wi-Fi Scale (Arm A) and Text for Diet (Text4Diet) Group (Arm B) in people with Endometrial Cancer, run by Fred Hutchinson Cancer Center at 3 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This randomized, controlled study evaluates the efficacy of weigh loss interventions in endometrial cancer survivors, using novel technology-based weight loss platforms. This is a multi-site, pilot feasibility study which will provide preliminary data to support a larger NIH funded, mult-center trial. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Endometrial Cancer
What is being tested?
Telemedicine Weight Management plus Wi-Fi Scale (Arm A) and Text for Diet (Text4Diet) Group (Arm B)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
207 participants
Where
3 sitesUnited States
Study dates
Jul 2014to Jun 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aim 2
  • Women 18 years of age or older and with biopsy-proven endometrial cancer,
  • Body Mass Index (BMI) greater than or equal to 30 kg/m2 (based on most recent routine clinical measurement recorded in patient's medical record),
  • Must be able to read and speak English fluently, and
  • All patients must be informed of the investigational nature of the Aim 2 survey study and must give written informed consent for Aim 2 study activities in accordance with institutional and federal guidelines. (Aim 2 consent is obtained and documented as described on page 1 of the Endometrial Cancer Questionnaire).
  • Aim 1
Show all 14Show fewer
  • Woman who was recruited to and completed Aim 2 of the study,
  • Has completed prior surgical or other medical management and adjuvant endometrial cancer treatment, prior to starting Aim 1,
  • Is not receiving concurrent cytotoxic chemotherapy and/or radiation therapy at time of randomization AND, after randomization, it is not anticipated that the participant will need to receive concurrent cytotoxic chemotherapy and/or radiation therapy at any time during the Aim 1 intervention,
  • No evidence of active endometrial cancer disease as determined by physician evaluation prior to randomization,
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy of at least one year,
  • Must have access to either wireless Internet, or a smart phone such as an Android or Apple iPhone, and
  • All patients must be informed of the investigational nature of this study and must sign and give written informed consent for Aim 1 study activities in accordance with institutional and federal guidelines.

Who cannot join

  • Aim 2
  • Must not have any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with Aim 2 protocol compliance or a participant's ability to give informed consent.
  • 4.3.2.2 Aim 1
  • Must not be participating in another weight loss program or taking weight loss medications,
  • No uncontrolled serious medical or psychiatric condition(s) that would affect the patient's ability to participate in the interventional study, e.g., uncontrolled hypertension, symptomatic cardiac disease, or severe/uncontrolled depression as indicated by a Patient Health Questionnaire (PHQ-9) score >19, or a score of ≥1 on the suicidal ideation item (#9 on the PHQ-9)
  • No diagnoses of any other invasive malignancy other than endometrial cancer or non-melanoma skin cancer which required active treatment currently or within the last 5 years. Carcinosarcoma is not excluded as the investigators are including women with Type I and II endometrial cancer. For the purposes of the trial, carcinosarcoma falls into the Type II category.
Show all 10Show fewer
  • No diagnoses of autoimmune disorders (including lupus, rheumatoid arthritis, Siogren's syndrome, Crohn's disease and ulcerative colitis), immune-compromised disorders (i.e., HIV/AIDS),
  • Not receiving at time of randomization, and not expected to receive at any time during the Aim 1 intervention, any medications that may affect the inflammatory markers of interest (i.e., steroids, immunosuppressants or transplant medications), and
  • Must not have any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with Aim 1 protocol compliance or a participant's ability to give informed consent.
  • Must not be pregnant.

Trial locations and contacts

3 sites in 1 country.

United States3 sites

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • Washington University in St Louis (Siteman Cancer Center)

    St Louis, Missouri, 63110

Other trials in United States

About this study

Official title: Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)

This randomized, controlled study evaluates the efficacy of weigh loss interventions in endometrial cancer survivors, using novel technology-based weight loss platforms. This is a multi-site, pilot feasibility study which will provide preliminary data to support a larger NIH funded, mult-center trial.

Read the detailed description

Study Aims The relationship between endometrial cancer (EC) and obesity is well established. However, few studies have examined the acceptability and potential efficacy of an intervention to promote weight reduction and alter cancer-associated biomarkers in endometrial cancer survivors. This investigation has two specific aims.

Aim 1:

To compare the efficacy of novel technology-based weight loss interventions: a) telephone encounters and wireless scales, or b) smart phone personalized text messaging as compared to c) an enhanced usual care group for women with obesity and a history of endometrial cancer.

Hypothesis: Women in both the telemedicine and text intervention arms will lose significantly more weight than women in the enhanced usual care arm.

Aim 2:

1a) To explore patients' understanding of the relationship between obesity and endometrial cancer and, 1b) to survey the acceptability of novel and different approaches to weight loss.

Hypothesis: The investigators anticipate that this study will validate pilot data from a predecessor single-institution study demonstrating that >25% of patients will not be aware of the association between excess body weight and endometrial cancer. Investigators also will assess the acceptability of various interventions designed to promote weight loss (i.e. in person counseling, phone-based, text messaging) and predict a greater interest in interventions that require fewer in-person visits to the clinic.

Study Design

Aim 1:

  • 3 arm randomized controlled trial, weight loss intervention
  • Pre and post intervention patient reported psychosocial measures
  • Pre and post intervention Dual-energy X-ray absorptiometry (DEXA) to explore impact of weight loss on body fat distribution
  • Pre and post intervention analyses of the following biomarkers: insulin-like growth factor-binding protein 1 (IGFBP-1); adiponectin, vascular endothelial growth factor (VEGF), C reactive protein (CRP), interleukin 1-beta (IL1-beta), interleukin 2 (IL2), interleukin 6 (IL6), interleukin 7 (IL7), and interleukin 8 (IL8)

Aim 2: Patient-reported survey to assess knowledge of correlation of Body Mass Index (BMI) with endometrial cancer incidence

Study Population

Aim 2: Adult women with biopsy-proven endometrial cancer (Types I and II), BMI ≥ 30 kg/m2.

Aim 1: Aim 2 population plus Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1, no concurrent chemo or radiation therapy, and access to wireless internet and/or smart phone device.

Being tested
Telemedicine Weight Management plus Wi-Fi Scale (Arm A), Text for Diet (Text4Diet) Group (Arm B), Enhanced Usual Care Group (Arm C)
Keywords
BMI >= 30 kg/m2
Medical subject headings
Endometrial Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Telemedicine Weight Management plus Wi-Fi Scale (Arm A)Behavioural

    Also called Telemedicine Group

    Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.

  • Text for Diet (Text4Diet) Group (Arm B)Behavioural

    Also called Text4Diet Group

    Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.

  • Enhanced Usual Care Group (Arm C)Behavioural

    Also called Enhanced Usual Care Group

    Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.

Study groups in NCT02466061
Study groupRoleWhat they receive
Arm A: Telemedicine GroupExperimentalTelemedicine Weight Management plus Wi-Fi Scale (Arm A) Participants in the Telemedicine Group will receive a Wi-Fi Scale that measures weight, lean mass, and fat mass. Participants will receive 15-20 minute telephone counseling sessions by phone. Sessions will occur at routine intervals during the six month intervention period. All Aim 1 participants, including those randomized to Arm A, will complete a packet of psychosocial measures at baseline and 6 months (final assessment). Month 12 followup weight data also will be collected through medical record abstraction.
Receives: Behavioral: Telemedicine Weight Management plus Wi-Fi Scale (Arm A)
Arm B: Text for Diet (Text4Diet) GroupExperimentalText for Diet (Text4Diet) Group (Arm B) The intervention in this Arm involves delivery of Short Message Service (SMS) text messages to participants each day over the course of a 6 month intervention period. Participants will also receive a digital scale to track weight on a weekly basis. SMS text messages will be sent 2-3 times per day and will provide feedback, support, prompting, and strategies to adhere to behaviors associated with long-term weight management. All Aim 1 participants, including those randomized to Arm B, will complete a packet of psychosocial measures at baseline and 6 months (final assessment). Month 12 follow up weight data also will be collected through medical record abstraction.
Receives: Behavioral: Text for Diet (Text4Diet) Group (Arm B)
Arm C: Enhanced Usual Care GroupActive comparatorEnhanced Usual Care Group (Arm C) Participants will be provided with handouts based on American Cancer Society guidelines on healthy eating and exercise. All Aim 1 participants, including those randomized to Arm C, will complete a packet of psychosocial measures at baseline and 6 months (final assessment). Month 12 follow up weight data also will be collected through medical record abstraction.
Receives: Behavioral: Enhanced Usual Care Group (Arm C)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Weight (kilograms)

    Change in weight (in kilograms) of study participants randomized to one of three weight loss intervention programs will be assessed. Measurement of this change will be evaluated from weights taken at baseline (randomization) and six months, the conclusion of the intervention program.

    Measured: Change from Baseline Weight at 6 months

  2. Serum biomarker: Change in levels of Insulin-like growth factor-binding protein 1 (IGFBP-1), in ng/mL

    Change in IGFBP-1 (in ng/mL) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline IGFBP-1 at 6 months

  3. Serum biomarker: Change in levels of Adiponectin, in ug/mL

    Change in Adiponectin (in ug/mL) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline Adiponectin at 6 months

  4. Serum biomarker: Change in levels of Vascular Endothelial Growth Factor (VEGF), in pg/mL

    Change in VEGF (in pg/mL) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline VEGF at 6 months

  5. Serum biomarker: Change in Interleukin 1-beta (IL1-beta), in pg/mL

    Change in IL1-beta (in pg/mL) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline IL1-beta at 6 months

  6. Serum biomarker: Change in Interleukin 2 (IL2), in pg/mL

    Change in IL2 (in pg/mL) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline IL2 at 6 months

  7. Serum biomarker: Change in Interleukin 6 (IL6), in pg/mL

    Change in IL6 (in pg/mL) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline IL6 at 6 months

  8. Serum biomarker: Change in Interleukin 7 (IL7), in pg/mL

    Change in IL7 (in pg/mL) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline IL7 at 6 months

  9. Serum biomarker: Change in Interleukin 8 (IL8), in pg/mL

    Change in IL8 (in pg/mL) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline IL8 at 6 months

  10. Serum biomarker: Change in C reactive protein (CRP), in mg/L

    Change in CRP (in mg/L) of randomized study participants will be assessed in peripheral blood samples collected at baseline (randomization) and again at 6 months, the conclusion of the intervention program.

    Measured: Change from Baseline CRP at 6 months

Secondary outcomes (6)

  1. Knowledge of the association between obesity and endometrial cancer risk

    Participants' level of knowledge of the association between obesity and the risk of endometrial cancer will be assessed at baseline. Frequencies of categorical responses will be reported. The instrument used to collect this data is a participant completed Endometrial Cancer Questionnaire and was developed by the study investigators.

    Measured: Baseline

  2. Psychosocial measure: Change in Body Image

    Change in participants' self-reported body image will be assessed at baseline (randomization) and again at 6 months, the conclusion of the intervention program. Two validated, participant-completed instruments will be utilized to assess this outcome: the Multidimensional Body Self Relations Questionnaire-Appearance Subscales (MBSRQ-AS) and the Cancer-Related Body Image Scale (CRBI).

    Measured: Change from Baseline Body Image at 6 months

  3. Psychosocial measure: Change in Quality of Life

    Change in participants' self-reported quality of life will be assessed at baseline (randomization) and again at 6 months, the conclusion of the intervention program. One validated, participant-completed instrument will be utilized to assess this outcome: the 12-Item Short Form Health Survey (SF-12).

    Measured: Change from Baseline in Quality of Life at 6 months

  4. Psychosocial measure: Change in Mood

    Change in participants' self-reported quality of life will be assessed at baseline (randomization) and again at 6 months, the conclusion of the intervention program. One validated, participant-completed instrument will be utilized to assess this outcome: the Patient Health Questionnaire 9-Item Version (PHQ-9).

    Measured: Change from Baseline in Mood at 6 months

  5. Psychosocial measure: Change in Sexual Functioning

    Change in participants' self-reported sexual functioning will be assessed at baseline (randomization) and again at 6 months, the conclusion of the intervention program. Three validated, participant-completed instruments will be utilized to assess this outcome: the Female Sexual Function Index (FSFI), the Dyadic Adjustment Scale (DAS), and the Female Sexual Distress Scale-Revised (FSDS-R).

    Measured: Change from Baseline in Sexual Functioning at 6 months

  6. Psychosocial measure: Change in Physical Activity

    Change in participants' self-reported physical activity will be assessed at baseline (randomization) and again at 6 months, the conclusion of the intervention program. One validated, participant-completed instrument will be utilized to assess this outcome: the International Physical Activity Questionnaire Short Form (IPAQ).

    Measured: Change from Baseline Physical Activity at 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2015 (estimated)
  2. Study startJul 2014
  3. Primary completionJun 2016
  4. Study completionJun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
207 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02466061
Sponsor's protocol ID
TREC 1190
Other IDs
U01CA116850, U54CA155850, U54CA155496, U54CA155626
Status last verified
Jun 2016
First submitted
29 May 2015
Last updated
2 Jun 2016
Results posted
No
Data monitoring committee
No

Publications

  • Haggerty AF, Hagemann A, Barnett M, Thornquist M, Neuhouser ML, Horowitz N, Colditz GA, Sarwer DB, Ko EM, Allison KC. A Randomized, Controlled, Multicenter Study of Technology-Based Weight Loss Interventions among Endometrial Cancer Survivors. Obesity (Silver Spring). 2017 Nov;25 Suppl 2(Suppl 2):S102-S108. doi: 10.1002/oby.22021.

    PubMed 29086522

Questions about this trial

What is this clinical trial studying?

A study testing Telemedicine Weight Management plus Wi-Fi Scale (Arm A) and Text for Diet (Text4Diet) Group (Arm B) in people with Endometrial Cancer, run by Fred Hutchinson Cancer Center at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Weight (kilograms) (time frame: Change from Baseline Weight at 6 months). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02466061, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2016.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in